^
Association details:
| Biomarker: | CEACAM5 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
490P - Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Published date:
09/05/2022
Excerpt:
In the GC cohort, inclusion was restricted to those with high CEACAM5 expression (≥ 2+ intensity in ≥ 50% of tumor cells...All patients received tusamitamab ravtansine 100 mg/m2 Q2W....In the GC cohort, the BOR was SD in 6 patients (37.5%) and a median TTP of 1.7 months (95% CI, 1.18-2.60).
Trial ID:
